Similar articles

• The importance of differentiating ReoPro (c7E3 abciximab) induced thrombocytopenia from heparin-induced thrombocytopenia.

  Davidson SJ, Turner N, Clague JR, Oldershaw PJ, Burman JF. Davidson SJ, et al. Thromb Haemost. 1999 Nov;82(5):1560-1. Thromb Haemost. 1999. PMID: 10595660 No abstract available.
• Reversal of recurrent thrombocytopenia due to abciximab.

  Sharma V, Mascarenhas D. Sharma V, et al. J Invasive Cardiol. 2004 Sep;16(9):537-8. J Invasive Cardiol. 2004. PMID: 15353816 Review. No abstract available.
• Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia.

  Rondina MT, Walker A, Pendleton RC. Rondina MT, et al. Hosp Pract (1995). 2010 Apr;38(2):19-28. Hosp Pract (1995). 2010. PMID: 20469610 Free PMC article.
• Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.

  Nguyen N, Salib H, Mascarenhas DA. Nguyen N, et al. J Invasive Cardiol. 2001 Jan;13(1):56-8. J Invasive Cardiol. 2001. PMID: 11146690
• Drug-induced immune thrombocytopenia.

  Chong BH, Choi PY, Khachigian L, Perdomo J. Chong BH, et al. Hematol Oncol Clin North Am. 2013 Jun;27(3):521-40. doi: 10.1016/j.hoc.2013.02.003. Epub 2013 Apr 9. Hematol Oncol Clin North Am. 2013. PMID: 23714310 Review.